Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine vs cocktail analgesia for postoperative pain after lumbar TLIF
ChiCTR2400089275Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bupivacaine in lumbosacral disc disease, Herniated Lumbar Disk, lumbar spondylolisthesis and 1 more (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Postoperative dosage of remedial morphine hydrochloride, Time to first postoperative remedial analgesia and 2 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
bupivacaine
03
Conditions
lumbosacral disc diseaseHerniated Lumbar Disklumbar spondylolisthesispseudoarthrosis
Beyond the preview
Go deeper on ChiCTR2400089275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089275.